source
- STAT+: A new attack on AMA’s billing codesA key GOP lawmaker is broadening the party's efforts to combat health care fraud.STAT · 2mo ago↗ source
- Viridian data lift prospects for thyroid eye disease drugWhereas earlier Phase 3 results disappointed Wall Street, new findings in people with “chronic” disease were viewed by analysts as much more competitive with Amgen’s Tepezza.BioPharma Dive · 2mo ago↗ source
- STAT+: Are analysts too quick to gloss over Lilly’s liver case?Cytokinetics' Myqorzo's trial results, Johnson & Johnson's IBD therapy, and more biotech news from The ReadoutSTAT · 2mo ago↗ source